Pharmacology of Combined Ranolazine and Amiodarone Hydrohloride therapy to treat Atrial Fibrillation
Abstract
This review article presents the pharmacology of combined Amiodarone Hydrochloride and Ranolazine therapy specially in Atrial Fibrillation. Amiodarone Hydrochloride is Anti Arrhythmic agent. Ranolazine is a Anti Anginal agent. The Antianginal agent was used in Ischaemia. Amiodarone Hydrochloride is Antiarrhythmic agent and use in Arrhythmia and Atrial fibrillation. If Amiodarone Hydrochloride is administered in large quantities, the condition of patient becomes worse by occurrence of adverse effect of Thyroid toxicity due to presence of Iodine moiety in Amiodarone. The use of Ranolazine in combination with Amiodarone Hydrochloride has been proved to provide beneficial effect in Atrial Fibrillation. The combination therapy has fewer adverse effects. The mechanism of Amiodarone Hydrochloride and Ranolazine is quite different. Amiodarone Hydrochloride inhibit potassium channel and inactivated-state blocker of cardiac sodium channel while Ranolazine inhibit late inward sodium current (INa) in cardiac cell and activated-state blocker of cardiac sodium channel. The combination of both have decrease dose dependent side effect of Amiodarone Hydrochloride. Both the drugs were approved by US government and has been used in Atrial Fibrillation in US. The main objective of this review article is to provide pharmacological information of combined therapy of Amiodarone Hydrochloride and Ranolazine to researcher in development of combined dosage form of this.
References
2. Tripathi K.D., Essentials of Medical Pharmacology; Jaypee Brothers Medical Publishers (P) LTD, New Delhi, 2009, 8th Edn; 508-509.
3. H.P.Rang., M.M.Dale., J.M.Ritter., and R.J.Flower. Rang and dale’s Pharmacology; Elsevier, Mumbai, 2007, 11th Edn; pp 288.
4. Dan M.R., Goodman & Gillman’s The pharmacological basis of Therapeutics; The McGraw-Hill Companies Inc, New Delhi, 2006, 10th Edn; 953-954.
5. SLU Medicine Resident, “Mechanism of Action-Amiodarone”, March 2007, slu.resident.blogspot.in
6. Hasenfuss G and Maier L.S, “Mechanism of action of the new anti-ischemia drug ranolazine.” Clin. Res. Cardiol. 2008, 97(4), 222-226.
7. Luiz B, John C, Shryock and Heather F, “The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction.”, Eur Heart J Suppl. 2006, 8(supplement A), A10-A13
8. Carbon F, “Update on evidence for treatment with ranolazine in stable angina”, October 2013, PHARMACOLOGY ARTICLE.docx
9. Konstantinos CK, Nikolaso F, Demosthenes K, Vassileios S et.al., “Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation.” Europace.; 2014, 16(7); 973-979.
10. Fragakis N, koskinas K.C, Katritsis D.G, Pagourelias E.D et.al., “Comparision of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation.” Am J Cardiol. 2012, 110(5), 673-677.
11. Serge S, Alexandr B, Luiz B and Charles A, “Synergistic Electrophysiologic and Antiarrhythmic effects of the Combination of Ranolazine and Chronic Amiodarone in Canine Atria.” Circ Arrhythm Electrophysiol. 2009, 3(1); 88-95.
12. Antzelevich C, Burashnikov A, Shryock S and Belardinelli L. Method treating atrial fibrillation. European Patents EP2337559A2, 2009.
